Hearing Loss

Gene transfer lessens cisplatin-induced damage to auditory system

Published in Gene Therapy Weekly, September 5th, 2002

by Sonia Nichols, senior medical writer - Gene therapy administered prior to the induction of cisplatin chemotherapy might alleviate the potential for hearing loss in some cancer patients. It also holds the possibility for reducing hearing loss in people as they age, researchers say.

Cisplatin, a drug used for the treatment of cancer patients, can cause damage to auditory system cells when administered at high doses. The damage can lead to hearing loss. Scientists may have found a way to lessen the effects of cisplatin-induced ototoxicity, or auditory injury, with virus-based gene therapy, according to a report in Molecular Therapy.

"We...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry